Targeting PI3K signalling in cancer: opportunities, challenges and limitations

Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216

The phosphoinositide 3-kinase pathway

Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621

PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer

Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496

Multiscale modeling of tumor growth and angiogenesis: Evaluation of tumor-targeted therapy

Nivlouei, S. J., Soltani, M., Carvalho, J., Travasso, R. D. M., Salimpour, M. R., & Shirani, E. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009081 · Cited by 43

Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer

Vichas, A., Riley, A. K., Nkinsi, N. T., Kamlapurkar, S., Parrish, P. C. R., Lo, A., Duke, F. F., Chen, J., Fung, I., Watson, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24841-y · Cited by 43

Human Immunodeficiency Virus Type 1 Induces Lytic Cycle Replication of Kaposi's-Sarcoma-Associated Herpesvirus: Role of Ras/c-Raf/MEK1/2, PI3K/AKT, and NF-κB Signaling Pathways

Zhu, X., Zhou, F., Qin, D., Zeng, Y., Lv, Z., Yao, S., & Lu, C. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.03.055 · Cited by 41

Overcoming Treatment Resistance in HER2-Positive Breast Cancer

Puglisi, F., Minisini, A. M., Angelis, C. D., & Arpino, G. (2012) · Drugs · doi:10.2165/11634000-000000000-00000 · Cited by 41

TRAIL negatively regulates VEGF-induced angiogenesis via caspase-8-mediated enzymatic and non-enzymatic functions

Na, H.-J., Hwang, J.-Y., Lee, K.-S., Choi, Y. K., Choe, J., Kim, J.-Y., Moon, H.-E., Kim, K.-W., Koh, G. Y., Lee, H., et al. (2013) · Angiogenesis · doi:10.1007/s10456-013-9387-0 · Cited by 40

Inhibition of Polo-like Kinase 1 (Plk1) Enhances the Antineoplastic Activity of Metformin in Prostate Cancer

Shao, C., Ahmad, N., Hodges, K. B., Kuang, S., Ratliff, T., & Liu, X. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.596817 · Cited by 42

Fenofibrate induces G0/G1 phase arrest by modulating the PPARα/FoxO1/p27kip pathway in human glioblastoma cells

Han, D., Zhang, J., Wei, W., Tao, T., Hu, Q., Wang, Y., Wang, X., Liu, N., & You, Y. (2015) · Tumor Biology · doi:10.1007/s13277-014-3024-4 · Cited by 40

Systems biology of the metabolic network regulated by the Akt pathway

Mosca, E., Barcella, M., Alfieri, R. R., Bevilacqua, A., Canti, G. L., & Milanesi, L. (2011) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.08.004 · Cited by 40

Inhibition of PI3K/mTOR Overcomes Nilotinib Resistance in BCR-ABL1 Positive Leukemia Cells through Translational Down-Regulation of MDM2

Ding, J., Romani, J., Zaborski, M., MacLeod, R. A. F., Nagel, S., Drexler, H. G., & Quentmeier, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083510 · Cited by 41

Enhanced PI3K p110α Signaling Confers Acquired Lapatinib Resistance That Can Be Effectively Reversed by a p110α-Selective PI3K Inhibitor

Brady, S. W., Zhang, J., Seok, D., Wang, H., & Yu, D. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0518 · Cited by 40

A beta version of life: p110β takes center stage

Dbouk, H. A., & Backer, J. (2010) · Oncotarget · doi:10.18632/oncotarget.207 · Cited by 40

NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug

Caporali, S., Levati, L., Graziani, G., Muzi, A., Atzori, M. G., Bonmassar, E., Palmieri, G., Ascierto, P. A., & D’Atri, S. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-252 · Cited by 40

Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas

Anderson, J. L., Park, A., Akiyama, R., Tap, W. D., Denny, C. T., & Federman, N. C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133610 · Cited by 40

Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments

Lokadasan, R., James, F. V., Narayanan, G., & Prabhakaran, P. K. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2016.626 · Cited by 40

PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma

Eze, N., Lee, J., Yang, D., Zhu, F., Neumeister, V. M., Sandoval-Schaefer, T., Mehra, R., Ridge, J. A., Forastiere, A. A., Chung, C. H., et al. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.02.026 · Cited by 40

Anti‐tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL‐302 in neuroblastoma

Mohlin, S., Hansson, K., Radke, K., Martinez, S., Blanco‐Apiricio, C., Garcia‐Ruiz, C., Welinder, C., Esfandyari, J., O'Neill, M., Pastor, J., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201810058 · Cited by 40

Sodium Propionate Attenuates the Lipopolysaccharide-Induced Epithelial–Mesenchymal Transition via the PI3K/Akt/mTOR Signaling Pathway

Chen, D., Qiu, Y.-B., Gao, Z.-Q., Wu, Y., Wan, B.-B., Liu, G., Chen, J., Zhou, Q., Yu, R., & Pang, Q. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.0c01302 · Cited by 39

CD26 upregulates proliferation and invasion in keloid fibroblasts through an IGF-1-induced PI3K/AKT/mTOR pathway

Yu, X., Min, P., Xu, H., Zhang, Z., Zhang, Y., & Zhang, Y. (2020) · Burns & Trauma · doi:10.1093/burnst/tkaa025 · Cited by 40

Signaling to the ribosome in cancer—It is more than just mTORC1

Hannan, K. M., Sanij, E., Hein, N., Hannan, R. D., & Pearson, R. B. (2011) · IUBMB Life · doi:10.1002/iub.428 · Cited by 44

New insights into redox regulation of stem cell self-renewal and differentiation

Ren, F., Wang, K., Zhang, T., Jiang, J., Nice, E. C., & Huang, C. (2015) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2015.02.017 · Cited by 42

Survival advantages conferred to colon cancer cells by E-selectin-induced activation of the PI3K-NFκB survival axis downstream of Death receptor-3

Porquet, N., Poirier, A., Houle, F., Pin, A.-L., Gout, S., Tremblay, P., Paquet, É. R., Klinck, R., Auger, F. A., & Huot, J. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-285 · Cited by 40

Insulin-Like Growth Factors and Insulin: At the Crossroad Between Tumor Development and Longevity

Novosyadlyy, R., & LeRoith, D. (2012) · The Journals of Gerontology Series A · doi:10.1093/gerona/gls065 · Cited by 41

Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition

Coco, S., Truini, A., Alama, A., Bello, M. G. D., Venè, R., Garuti, A., Carminati, E., Rijavec, E., Genova, C., Barletta, G., et al. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0344-7 · Cited by 40

Akt Activation Emulates Chk1 Inhibition and Bcl2 Overexpression and Abrogates G2 Cell Cycle Checkpoint by Inhibiting BRCA1 Foci

Tonic, I., Yu, W.-N., Park, Y., Chen, C.-C., & Hay, N. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.104372 · Cited by 39

Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations

Bonelli, M. A., Cavazzoni, A., Saccani, F., Alfieri, R. R., Quaini, F., Monica, S. L., Galetti, M., Cretella, D., Caffarra, C., Madeddu, D., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0892 · Cited by 39

Targeted proteomic approach in prostatic tissue: a panel of potential biomarkers for cancer detection

Aiello, D., Casadonte, F., Terracciano, R., Damiano, R., Savino, R., Sindona, G., & Napoli, A. (2016) · Oncoscience · doi:10.18632/oncoscience.313 · Cited by 39

Direct binding of MEK1 and MEK2 to AKT induces Foxo1 phosphorylation, cellular migration and metastasis

Procaccia, S., Ordan, M., Cohen, I., Bendetz-Nezer, S., & Seger, R. (2017) · Scientific Reports · doi:10.1038/srep43078 · Cited by 40

Covalent binding design strategy: A prospective method for discovery of potent targeted anticancer agents

Wang, L., Zhao, J., Yao, Y., Wang, C., Zhang, J., Shu, X. H., Sun, X., Li, Y., Liu, K., Yuan, H., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.024 · Cited by 39

The impact of phosphatases on proliferative and survival signaling in cancer

Narla, G., Sangodkar, J., & Ryder, C. B. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2826-8 · Cited by 39

TFAP4 Promotes Hepatocellular Carcinoma Invasion and Metastasis via Activating the PI3K/AKT Signaling Pathway

Huang, T., Chen, Q., Chang, B.-Y., Shen, L., Li, W., Wu, P., & Fan, W. (2019) · Disease Markers · doi:10.1155/2019/7129214 · Cited by 39

Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach

Ranganna, K., Selvam, C., Shivachar, A. C., & Yousefipour, Z. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218198 · Cited by 40

Novel PI3K/Akt/mTOR signaling inhibitor, W922, prevents colorectal cancer growth via the regulation of autophagy

Wang, J., Dong, L., Zhang, X., He, C., Cao, L., Zhang, S., Xiao, X., Li, S., & Cao, Y. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5151 · Cited by 41

Erufosine suppresses breast cancer in vitro and in vivo for its activity on PI3K, c-Raf and Akt proteins

Dineva, I. K., Zaharieva, M. M., Konstantinov, S., Eibl, H., & Berger, M. R. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1271-6 · Cited by 39

The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication

Michaelis, M., Paulus, C., Löschmann, N., Dauth, S., Stange, E., Doerr, H. W., Nevels, M. M., & Cinatl, J. J. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0510-8 · Cited by 40

Development of anticancer drugs based on the hallmarks of tumor cells

Bailón-Moscoso, N., Romero-Benavides, J. C., & Ostrosky‐Wegman, P. (2014) · Tumor Biology · doi:10.1007/s13277-014-1649-y · Cited by 44

Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer

Li, X., Tong, L., Ding, J., & Meng, L. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.046 · Cited by 39

An Anti‐Cancer Drug Candidate OSI‐027 and its Analog as Inhibitors of mTOR: Computational Insights Into the Inhibitory Mechanisms

Rehan, M. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26117 · Cited by 39

Characterizing Tyrosine Phosphorylation Signaling in Lung Cancer Using SH2 Profiling

Machida, K., Eschrich, S. A., Li, J., Bai, Y., Koomen, J. M., Mayer, B. J., & Haura, E. B. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013470 · Cited by 38

Renal cell carcinoma: translational aspects of metabolism and therapeutic consequences

Yang, O. C. Y., Maxwell, P. H., & Pollard, P. J. (2013) · Kidney International · doi:10.1038/ki.2013.245 · Cited by 38

Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer

Nagaraj, G., & Ma, C. X. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3316-4 · Cited by 38

The Novel Hsp90 Inhibitor NXD30001 Induces Tumor Regression in a Genetically Engineered Mouse Model of Glioblastoma Multiforme

Zhu, H., Woolfenden, S., Bronson, R. T., Jaffer, Z. M., Barluenga, S., Winssinger, N., Rubenstein, A. E., Chen, R., & Charest, A. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0248 · Cited by 38

Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: Current evidence and future perspectives

Custodio, A., Barriuso, J., de Castro, J., Martínez-Marín, V., Moreno, V., Rodrı́guez-Salas, N., & Feliú, J. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.02.004 · Cited by 38

Utility of mTOR Inhibition in Hematologic Malignancies

Younes, A., & Samad, N. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0318 · Cited by 38

Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia

Palomba, G., Colombino, M., Contu, A. S., Massidda, B., Baldino, G., Pazzola, A., Ionta, M. T., Capelli, F., Trova, V., Sedda, T., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-178 · Cited by 38

Discovery of Novel and Orally Bioavailable Inhibitors of PI3 Kinase Based on Indazole Substituted Morpholino-Triazines

Dugar, S., Hollinger, F. P., Mahajan, D., Sen, S., Kuila, B., Arora, R., Pawar, Y. B., Shinde, V., Rahinj, M., Kapoor, K. K., et al. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00322 · Cited by 38

A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600–Mutant Solid Tumors

Yam, C., Xu, X., Davies, M. A., Gimotty, P. A., Morrissette, J. J. D., Tetzlaff, M. T., Wani, K., Liu, S., Deng, W., Buckley, M. E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1807 · Cited by 38

EG-VEGF silencing inhibits cell proliferation and promotes cell apoptosis in pancreatic carcinoma via PI3K/AKT/mTOR signaling pathway

Yan, X., Hui, Y., Hua, Y., Huang, L., Wang, L., Peng, F., Tang, C., Liu, D., Song, J., & Wang, F. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.125 · Cited by 38

Tamoxifen and the PI3K Inhibitor: LY294002 Synergistically Induce Apoptosis and Cell Cycle Arrest in Breast Cancer MCF-7 Cells

Abdallah, M. E., El-Readi, M. Z., Althubiti, M., Almaimani, R. A., Ismail, A. M., Idris, S., Refaat, B., Almalki, W. H., Babakr, A. T., Mukhtar, M. H., et al. (2020) · Molecules · doi:10.3390/molecules25153355 · Cited by 38

Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS

Roskoski, R. J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105806 · Cited by 38

Varicella-Zoster Virus ORF12 Protein Activates the Phosphatidylinositol 3-Kinase/Akt Pathway To Regulate Cell Cycle Progression

Liu, X., & Cohen, J. I. (2012) · Journal of Virology · doi:10.1128/jvi.02395-12 · Cited by 38

Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity

Liu, K., Zhu, J., Smith, G. L., Yin, M.-J., Bailey, S., Chen, J. H., Hu, Q., Huang, Q., Li, C., Li, Q. J., et al. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200126j · Cited by 38

PIKing the right isoform: the emergent role of the p110β subunit in breast cancer

Carvalho, S., Milanezi, F., Costa, J. L., Amendoeira, I., & Schmitt, F. C. (2010) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-010-0881-0 · Cited by 38

Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma

Bisht, S., Ahmad, F., Sawaimoon, S. K., Bhatia, S., & Das, B. R. (2014) · Medical Oncology · doi:10.1007/s12032-014-0124-3 · Cited by 40

Histopathological Determinants of Tumor Resistance: A Special Look to the Immunohistochemical Expression of Carbonic Anhydrase IX in Human Cancers

Ilardi, G., Zambrano, N., Merolla, F., Siano, M., Varricchio, S., Vecchione, M. L., Rosa, G. D., Mascolo, M., & Staibano, S. (2014) · Current Medicinal Chemistry · doi:10.2174/09298673113209990227 · Cited by 38

DA6034 promotes gastric epithelial cell migration and wound‐healing through the mTOR pathway

Kim, Y., Lee, W. H., Choi, S. M., Seo, Y. Y., Ahn, B. O., Kim, S. H., & Kim, S. G. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06873.x · Cited by 38

PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K α Inhibitors

Croessmann, S., Sheehan, J. H., Lee, K., Sliwoski, G. R., He, J., Nagy, R. J., Riddle, D., Mayer, I. A., Balko, J. M., Lanman, R. B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2141 · Cited by 38

Targeting the PI 3K signaling pathway in KRAS mutant colon cancer

Hong, S., Kim, S., Kim, H. Y., Kang, M., Jang, H. H., & Lee, W. (2016) · Cancer Medicine · doi:10.1002/cam4.591 · Cited by 37

Genetic Variations in STK11, PRKAA1, and TSC1 Associated with Prognosis for Patients with Colorectal Cancer

Lee, S. J., Kang, B. W., Chae, Y. S., Kim, H. J., Park, S., Park, J. S., Choi, G., Jeon, H.-S., Lee, W. K., & Kim, J. G. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3729-z · Cited by 36

Growth factor and signaling pathways and their relevance to prostate cancer therapeutics

Wozney, J. L., & Antonarakis, E. S. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9475-z · Cited by 38

PI3K/mTOR Signaling in Mesothelioma Patients Treated with Induction Chemotherapy Followed by Extrapleural Pneumonectomy

Bitanihirwe, B. K. Y., Meerang, M., Friess, M., Soltermann, A., Frischknecht, L., Thies, S., Felley‐Bosco, E., Tsao, M., Allo, G., de Perrot, M. E., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000055 · Cited by 37

Higher Risk of Infections with PI3K–AKT–mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials

Rafii, S., Roda, D., Geuna, E., Jiménez, B., Rihawi, K., Capelán, M., Yap, T. A., Molife, L. R., Kaye, S. B., Bono, J. S. D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2424 · Cited by 38

Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Kadara, H. N., Shen, L., Fujimoto, J., Saintigny, P., Chow, C.-W. B., Lang, W., Chu, Z., Garcia, M. M., Kabbout, M., Fan, Y.-H., et al. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0290 · Cited by 37

Preclinical Assessment of the Absorption and Disposition of the Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor GDC-0980 and Prediction of Its Pharmacokinetics and Efficacy in Human

Salphati, L., Pang, J., Plise, E. G., Lee, L. B., Olivero, A. G., Prior, W. W., Sampath, D., Wong, S., & Zhang, X. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.046052 · Cited by 37

Advances in sarcoma gene mutations and therapeutic targets

Gao, P., Seebacher, N. A., Hornicek, F. J., Guo, Z., & Duan, Z. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.001 · Cited by 37

Inhibition of cell migration by focal adhesion kinase: Time-dependent difference in integrin-induced signaling between endothelial and hepatoblastoma cells

Yu, H., Gao, M., Ma, Y., Wang, L., Shen, Y., & Liu, X. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3512 · Cited by 37

TRIM11 promotes proliferation and glycolysis of breast cancer cells via targeting AKT/GLUT1 pathway

Song, W., Wang, Z., Gu, X. Q., Wang, A., Chen, X., Miao, H., Chu, J., & Tian, Y. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s207723 · Cited by 37

Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer

Lai, E., Liscia, N., Donisi, C., Mariani, S., Tolu, S., Pretta, A., Persano, M., Pinna, G., Balconi, F., Pireddu, A., et al. (2020) · Cancers · doi:10.3390/cancers12051214 · Cited by 37

Erb‑B2 Receptor Tyrosine Kinase 2 is negatively regulated by the p53‑responsive microRNA‑3184‑5p in cervical cancer cells

Liu, H., Li, Y., Zhang, J., Wu, N., Liu, F., Wang, L., Zhang, Y., Liu, J., Zhang, X., Guo, S., et al. (2020) · Oncology Reports · doi:10.3892/or.2020.7862 · Cited by 37

An acetyl-histone vulnerability in PI3K/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors

Wu, D., Yan, Y., Wei, T., Ye, Z., Xiao, Y., Pan, Y., Orme, J. J., Wang, D., Wang, L., Ren, S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108744 · Cited by 37

Exposure to trace levels of metals and fluoroquinolones increases inflammation and tumorigenesis risk of zebrafish embryos

Jia, D., Zhang, R., Shao, J., Zhang, W., Cai, L., & Sun, W. (2022) · Environmental Science and Ecotechnology · doi:10.1016/j.ese.2022.100162 · Cited by 36

Systems pharmacology-based drug discovery for marine resources: An example using sea cucumber (Holothurians)

Guo, Y., Ding, Y., Xu, F., Liu, B., Kou, Z., Xiao, W., & Zhu, J. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2015.02.029 · Cited by 37

Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors

Dehnhardt, C. M., Venkatesan, A. M., Chen, Z., Santos, E. D., Ayral‐Kaloustian, S., Brooijmans, N., Yu, K., Hollander, I. J., Feldberg, L. R., Lucas, J., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.06.063 · Cited by 37

Dietary energy balance modulates ovarian cancer progression and metastasis

Al-Wahab, Z. R., Tebbe, C., Chhina, J., Dar, S. A., Morris, R. T., Ali‐Fehmi, R., Giri, S., Munkarah, A. R., & Rattan, R. (2014) · Oncotarget · doi:10.18632/oncotarget.2168 · Cited by 36

Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary

Sasano, T., Mabuchi, S., Kuroda, H., Kawano, M., Matsumoto, Y., Takahashi, R., Hisamatsu, T., Sawada, K., Hashimoto, K., Isobe, A., et al. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0314 · Cited by 37

SAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis

Kodigepalli, K. M., Bonifati, S., Tirumuru, N., & Wu, L. J. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1480218 · Cited by 36

Effect of the Large and Small T-Antigens of Human Polyomaviruses on Signaling Pathways

Moens, U. L., & Macdonald, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163914 · Cited by 38

Weight control and cancer preventive mechanisms: Role of insulin growth factor-1-mediated signaling pathways

Xie, L., & Wang, W. (2013) · Experimental Biology and Medicine · doi:10.1177/1535370213477602 · Cited by 36

1,25-Dihydroxyvitamin D3 and the aging-related Forkhead Box O and Sestrin proteins in osteoblasts

Eelen, G., Verlinden, L., Meyer, M. B., Gijsbers, R., Pike, J. W., Bouillon, R., & Verstuyf, A. (2012) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2012.09.011 · Cited by 36

Epigenetic Inactivation of Inositol polyphosphate 4-phosphatase B (INPP4B), a Regulator of PI3K/AKT Signaling Pathway in EBV-Associated Nasopharyngeal Carcinoma

Yuen, J. W.-F., Chung, G. T., Lun, S. W., Cheung, C. C., To, K., & Lo, K. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105163 · Cited by 36

Inhibitors of phosphatidylinositol-3-kinase in cancer therapy

Ihle, N., & Powis, G. (2010) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2010.02.003 · Cited by 40

Pharmacogenetics of EGFR in Lung Cancer: Perspectives and Clinical Applications

Mayo, C., Bertrán-Alamillo, J., Molina‐Vila, M. Á., Giménez-Capitán, A. A., Costa, C., & Rosell, R. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.54 · Cited by 36

Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models

Crafter, C., VINCENT, J. P., TANG, E. K. Y., Dudley, P., James, N. H., Klinowska, T. C. M., & Davies, B. R. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3062 · Cited by 36

Genomics of Squamous Cell Lung Cancer

Rooney, M., Devarakonda, S. H. K., & Govindan, R. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0063 · Cited by 37

Targeting phosphoinositide 3-kinase signalling in lung cancer.

Wojtalla, A., & Arcaro, A. (2011) · Critical reviews in oncology/hematology · doi:10.1016/j.critrevonc.2011.01.007 · Cited by 41

PIK3CA Activating Mutations: A Discordant Role in Early Versus Advanced Hormone-Dependent Estrogen Receptor–Positive Breast Cancer?

Mayer, I. A., & Arteaga, C. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.9591 · Cited by 37

Exploring a Non-ATP Pocket for Potential Allosteric Modulation of PI3Kα

Gkeka, P., Papafotika, A., Christoforidis, S., & Cournia, Z. (2014) · The Journal of Physical Chemistry B · doi:10.1021/jp506423e · Cited by 36

Targeted Therapies Combined With Immune Checkpoint Therapy

Prieto, P. A., Reuben, A., Cooper, Z. A., & Wargo, J. A. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000182 · Cited by 37

Anticancer compound XL765 as PI3K/mTOR dual inhibitor: A structural insight into the inhibitory mechanism using computational approaches

Rehan, M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219180 · Cited by 36

Insulin Exacerbates Inflammation in Fibroblast-Like Synoviocytes

Qiao, L., Li, Y., & Sun, S. (2020) · Inflammation · doi:10.1007/s10753-020-01178-0 · Cited by 37

How can we turn the PI3K/AKT/mTOR pathway down? Insights into inhibition and treatment of cancer

Afify, S. M., Oo, A. K. K., Hassan, G., Seno, A., & Seno, M. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1918001 · Cited by 36

Evi1 forms a bridge between the epigenetic machinery and signaling pathways

Yoshimi, A., & Kurokawa, M. (2011) · Oncotarget · doi:10.18632/oncotarget.304 · Cited by 36

ZSTK474, a specific phosphatidylinositol 3-kinase inhibitor, induces G1 arrest of the cell cycle in vivo

Dan, S., Okamura, M., Mukai, Y., Yoshimi, H., Inoue, Y., Hanyu, A., Sakaue-Sawano, A., Imamura, T., Miyawaki, A., & Yamori, T. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.006 · Cited by 36

Predicting Response to EGFR Inhibitors in Metastatic Colorectal Cancer: Current Practice and Future Directions

Shankaran, V., Obel, J. C., & Benson, A. B. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0221 · Cited by 36

Lung Endothelial MicroRNA-1 Regulates Tumor Growth and Angiogenesis

Korde, A., Jin, L., Zhang, J.-G., Ramaswamy, A., Hu, B., Kolahian, S., Guardela, B. J., Herazo‐Maya, J. D., Siegfried, J. M., Stabile, L. P., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201610-2157oc · Cited by 36

Cyclosporin A inhibits colon cancer cell growth independently of the calcineurin pathway

Werneck, M. B. F., Hottz, E. D., Bozza, P. T., & Viola, J. P. B. (2012) · Cell Cycle · doi:10.4161/cc.22222 · Cited by 35

RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanoma

Laugier, F., Finet, A., André, J., Rachakonda, P. S., Kumar, R., Bensussan, A., & Dumaz, N. (2015) · Oncotarget · doi:10.18632/oncotarget.4866 · Cited by 35

Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC

Potter, D. S., Galvin, M., Brown, S., Lallo, A., Hodgkinson, C. L., Blackhall, F. H., Morrow, C. J., & Dive, C. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0885 · Cited by 35

Rolipram potentiates bevacizumab-induced cell death in human glioblastoma stem-like cells

Ramezani, S., Vousooghi, N., Kapourchali, F. R., Hadjighassem, M., Hayat, P., Amini, N., & Joghataei, M. T. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.02.005 · Cited by 35

Cryptotanshinone inhibition of mammalian target of rapamycin pathway is dependent on oestrogen receptor alpha in breast cancer

Pan, Y., Shi, J., Ni, W., Liu, Y., Wang, S., Wang, X., Wei, Z., Wang, A., Chen, W., & Lu, Y. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13135 · Cited by 35

Isofraxidin inhibited proliferation and induced apoptosis via blockage of Akt pathway in human colorectal cancer cells

Shen, P., Wang, H., Li, M., Ma, Q., Zhou, C., Pan, F., & Xie, R. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.05.065 · Cited by 35

Targeting the phosphoinositide 3-kinase pathway in cancer

Liu, P., Cheng, H.-L. M., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,785

Targeting PI3K/Akt signal transduction for cancer therapy

He, Y., Sun, M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 2,045

Molecular targeting: PI3 kinase pathway

Dancey, J. E. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh932 · Cited by 54

Akt inhibitors in cancer therapy

Alam, M., Ali, S., & Hassan, M. I. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91287-7.00006-5 · Cited by 6

Targeting the PI3K pathway in cancer: are we making headway?

Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033